Neuroendocrine Tumors

Neuroendocrine Tumors

Ga-68 and Cu-64 tagged Somatostatin Analogs

Schedule

• Lecture: Introduction to neuroendocrine tumors (NETs) and their pathophysiology.

• Break: Time for students to reflect and discuss.

• Lecture: Detailed exploration of somatostatin receptor imaging and treatment implications.

• Case Studies: Analysis of real-world NET cases to enhance understanding.

Objectives

• Upon completion of this lecture, students will be able to:

  • Understand the pathophysiology of neuroendocrine tumors, including the intricate mechanisms underlying tumor growth, metastasis, and their interactions with the endocrine system.

  • Differentiate between various types of somatostatin receptor radiopharmaceuticals, focusing on their pharmacodynamics, pharmacokinetics, and clinical applications in diagnostic imaging and treatment.

  • Describe in detail the protocol for somatostatin receptor PET/CT studies, emphasizing preparation steps, imaging techniques, and patient management considerations.

  • Explain the normal biodistribution for NET imaging, highlighting factors influencing the uptake of radiopharmaceuticals and their clinical significance in diagnosis.

  • Analyze NET PET/CT images using advanced imaging software to enhance diagnostic accuracy through understanding of imaging artifacts and physiological variants.

  • Recognize pathology on NET PET/CT studies and discuss clinical implications for personalized treatment planning, including the role of radiopharmaceuticals.

Somatostatin

• Also known as:

  • Growth hormone-inhibiting hormone (GHIH): Plays a critical role in the regulation of growth hormone levels and overall metabolic processes.

  • Somatotropin release-inhibiting factor (SRIF): Regulates other hormones related to growth and metabolism, acting as a key component of the endocrine system.

  • Somatotropin release-inhibiting hormone: Essential for modulating hormonal release in both the anterior pituitary and peripheral endocrine glands.

• Regulates the endocrine system:

  • Release is triggered by low pH, particularly in the gastrointestinal tract and in response to various nutrient stimuli, impacting digestive and hormonal functions.

Pituitary Actions:

• Inhibits the release of vital hormones:

  • Growth Hormone: Essential for growth, metabolism, and muscle development, too much or too little can lead to endocrine disorders.

  • Thyroid-stimulating hormone (TSH): Plays a crucial role in regulating metabolism through thyroid hormone production, abnormalities in TSH can lead to thyroid disorders.

  • Prolactin: Involved in lactation and reproductive health, with implications for fertility and hormonal balance.

• Inhibits adenylyl cyclase in parietal cells, thereby reducing gastric acid secretion, which can influence gastrointestinal health.

Gastrointestinal System Actions:

• Inhibits the release of various hormones impacting digestive processes:

  • Gastrin: Stimulates gastric acid secretion, and excessive levels can lead to peptic ulcers.

  • Cholecystokinin (CCK): Promotes gallbladder contraction and digestive enzyme release, critical for fat digestion.

  • Secretin: Promotes bicarbonate secretion from the pancreas, neutralizing gastric acid in the intestines.

  • Motilin, Vasoactive intestinal peptide, Gastric inhibitory polypeptide, Enteroglucagon: These hormones collectively regulate gut motility, enzyme secretion, and nutrient absorption.

• Decreases the rate of gastric emptying, enhancing nutrient absorption and contributing to satiety.

• Reduces smooth muscle contractions and blood flow within the intestine, influencing digestive processes, and can impact conditions like irritable bowel syndrome.

Pancreas Actions:

• Suppresses the release of pancreatic hormones, which are vital for glucose metabolism:

  • Insulin: Decreases blood glucose levels; dysregulation can lead to diabetes.

  • Glucagon: Raises blood glucose levels; essential in maintaining glucose homeostasis.

Neuroendocrine Tumors (NETs)

• Sometimes referred to as somatostatin receptor tumors due to their higher number of somatostatin receptors, which have significant implications for diagnosis and treatment strategies.

• Treatment options:

  • Somatostatin analog drugs such as Octreotide:

    • Suppresses the function and proliferation of tumors, aiding in the control of symptoms like carcinoid syndrome.

    • Can be radiolabeled with isotopes for diagnostic purposes, enhancing imaging capabilities and allowing targeted therapy.

Classification of NETs

• Foregut:

  • Contains tumors originating from the thymus, esophagus, lung, stomach, duodenum, and pancreas, often associated with various clinical syndromes.

• Midgut:

  • Includes appendix, small bowel, cecum, and ascending colon, known for often presenting with carcinoid syndrome.

• Hindgut:

  • Comprises the distal large bowel and rectum, where tumors can lead to different clinical outcomes and therapeutic approaches.

Types of Functional Tumors in the Pancreas

• Insulinoma: Produces excess insulin, leading to symptomatic hypoglycemia, requiring careful management strategies.

• Gastrinoma: Releases excessive gastrin, resulting in Zollinger-Ellison syndrome, characterized by recurrent ulcers and severe abdominal pain.

• Glucagonoma: Associated with hyperglycemia and significant weight loss, often requiring multi-disciplinary management.

• VIPoma: Produces vasoactive intestinal peptide, causing profuse watery diarrhea, leading to electrolyte imbalances.

• Pancreatic polypeptidoma: Affects appetite and digestive fluid secretion, complicating weight management strategies.

Neuroendocrine Tumors of the Foregut

• Each embryological division has distinct blood supply, impacting both diagnosis and treatment strategies for NETs.

• Foregut tumors typically originate from the esophagus to the duodenum at the level of the major duodenal papilla, affecting a significant number of patients and necessitating collaborative care approaches.

High SST Expression Tumors

• Tumors displaying high expression of somatostatin receptors (SST) include:

  • Gastroenteropancreatic tumors: e.g., carcinoids and gastrinomas are prime examples.

  • Functioning and nonfunctioning sympathoadrenal system tumors: e.g., pheochromocytoma and paraganglioma.

  • Other significant tumors:

    • Medullary thyroid carcinoma

    • Pituitary adenoma

    • Medulloblastoma

    • Merkel cell carcinoma

    • Small-cell lung cancer (mainly primary tumors)

    • Meningioma

Carcinoid Tumors

• Definition: A slow-growing neuroendocrine tumor originating from neuroendocrine cells, often arising from the gastrointestinal tract, with potential for systemic impact.

• Characteristics:

  • Often asymptomatic in early stages, they can cause significant symptoms due to hormone over-secretion, leading to delays in diagnosis.

  • Common symptoms include:

    • Flushing: Episodes of redness or warmth in the face and neck.

    • Diarrhea: Often severe and debilitating, representing a significant issue for quality of life.

    • Wheezing: Indicative of bronchoconstriction, common in advanced disease.

    • Abdominal cramping: Due to peptide release, impacting nutrition and comfort.

    • Peripheral edema: Fluid retention contributing to discomfort.

  • Metastasis can lead to carcinoid syndrome, characterized by a distinct set of symptoms, significantly impacting quality of life, necessitating close monitoring and personalized treatment approaches.

Carcinoid Syndrome

• Caused by endogenous secretion of mainly:

  • Serotonin and kallikrein: These hormones lead to systemic effects characterized by flushing and diarrhea.

• Symptoms may include:

  • Hyperhistamine response: Resulting in flushing and allergic responses, complicating patient symptomatology.

  • Increased serotonin: Leading to various complications such as:

    • Liver disease

    • Asthma exacerbations

    • Restrictive cardiomyopathy, necessitating monitoring of cardiac function.

Diagnostic Exams:

• The most sensitive and specific diagnostic tool is the Octreoscan (90% sensitivity), essential for early detection of NETs, especially in atypical presentations.

• CT and MRI are adjuncts with 75%-80% sensitivity and are useful for complex cases, enhancing the diagnostic arsenal available to clinicians.

• Other therapies include peptide receptor radionuclide therapy (PRRT) with isotopes like lutetium-177, yttrium-90, or indium-111, crucial for targeted therapy approaches for advanced NETs.

Clinical Presentation of Carcinoid Syndrome

• Heart:

  • Pulmonary and tricuspid fibrosis: A major contributor to cardiac complications often seen in systemic disease progression.

• Skin:

  • Facial flushing: Linked to elevated serotonin levels in circulation, requiring management in symptomatic patients.

• Liver:

  • Hepatomegaly: Indicative of metastasis or storage disorders, warranting investigation and close monitoring.

• Respiratory:

  • Symptoms like cough, wheezing, and dyspnea due to bronchoconstriction or lung metastasis, necessitating pulmonary function evaluations.

• Gastrointestinal:

  • Symptoms including diarrhea, nausea, vomiting, and abdominal cramps, affecting nutrition, hydration status, and quality of life.

• Retroperitoneal and Pelvic:

  • Fibrosis can lead to obstructive symptoms or pain, requiring careful symptom management strategies and potential surgical considerations.

Radiopharmaceuticals Used in Nuclear Medicine

• In-111 Octreoscan (Pentetreotide): A critical somatostatin analog designed to bind specifically to somatostatin receptors, aiding in the diagnosis of NETs with high specificity.

• I-131 MIBG (Iobenguane): Effective in diagnosing pheochromocytoma and neuroblastoma, maximizing diagnostic capabilities through targeted imaging.

• I-123 MIBG: Provides similar applications with distinct imaging characteristics that enhance diagnostic accuracy.

• Ga-68 Dotatate/Dotatoc/Dotanoc: Modern agents improving target specificity for somatostatin receptor imaging, vital for early diagnosis.

• Cu-64 Dotatate: Emerging technologies supporting improved imaging results and diagnostics, crucial in advancing patient care.

Copper-64 (Cu-64)

• Characteristics:

  • Half-life: $T_{1/2} = 12.7 ext{ hours}$, balancing optimal imaging needs with patient safety considerations.

  • Production methods include cyclotron or reactor reactions (via $^{64} ext{Ni}(p,n)^{64} ext{Cu}$), impacting availability and usage in clinical settings.

  • Uses:

    • FDA approved for Cu-64 Dotatate, linked to bioactive molecules for various malignancies and diagnostic applications in diseases, including Alzheimer's and atherosclerosis.

Cu-64 Dotatate (Detectnet®)

• Administration Details:

  • Half-life: $12.7 ext{ hours}$ facilitates extended imaging capabilities post-administration.

  • Decay pathways:

    • 17.6% by positron emission to $^{64} ext{Ni}$ (emission of two 511 keV annihilation photons).

    • 38.5% by beta decay to $^{64} ext{Zn}$.

    • 43.8% by electron capture to $^{64} ext{Ni}$.

    • 0.475% by gamma radiation/internal conversion, relevant for imaging interpretation.

• Mechanism of Action:

  • Binds to somatostatin receptors, particularly with the highest affinity for subtype 2 receptors (SSTR2), which significantly enhances imaging accuracy for neuroendocrine tumors.

• Indications:

  • For localization of somatostatin receptor-positive neuroendocrine tumors (NETs) in adult patients, facilitating targeted therapy approaches tailored to individual tumor characteristics.

• Contraindications:

  • None specified; however, caution with somatostatin analogs is warranted, as they may competitively bind to SSTR2, potentially affecting imaging outcomes and patient management.

• Patient Recommendations:

  • Administer 148 MBq (4 mCi) via intravenous injection over 1 minute, ensuring accurate dosing and minimal patient distress, with imaging commencing 45 to 90 minutes post-injection for optimal results.

Imaging with Cu-64 Dotatate

• Storage:

  • Store in a lead glass shield container at temperatures below $77^{ ext{o}}F$ ($25^{ ext{o}}C$) until use to maintain efficacy and safety.

• Critical Organs:

  • Liver, kidneys/adrenals, spleen: Awareness of radiation exposure is crucial during imaging procedures to minimize patient risk, necessitating protective measures.

• Areas of Normal Uptake:

  • Binds to somatostatin receptors, allowing observation via PET technology, indicating both tumor presence and distribution; variability in uptake may include physiological variants not directly related to NETs, requiring careful interpretation during analysis.

Comparison Figures

• Figure 2: Comparisons of imaging between In-111-DTPA-octreotide vs. Cu-64-DOTA-TATE highlight differences in sensitivity and specificity in patients with multiple bone and soft-tissue metastases for optimizing treatment options.

Gallium-68 (Ga-68)

• Characteristics:

  • Produced via generators (68GE-Ga68 Generator), improving accessibility for clinical use in diagnosing NETs.

  • Half-life: $68 ext{ minutes}$, providing a balance between imaging time and patient safety concerning radiation exposure.

• Mechanism of Action:

  • Ga-68 binds to somatostatin receptors, primarily utilized in localizing somatostatin receptor-positive NETs with high sensitivity, crucial for accurate diagnostic imaging.

• Clinical Use:

  • For diagnostics in both adult and pediatric patients, demonstrating wide applicability across demographics and different disease stages.

• Contraindications:

  • Pregnancy/nursing (not absolute), emphasizing the necessity for careful risk assessment during imaging procedures involving potential fetal exposure.

Ga-68 Dotatate and Dotatoc

• Administration:

  • Recommended dose: 2 MBq/kg body weight (0.054 mCi/kg), maximum of 200 MBq (5.4 mCi), maintaining dosage accuracy for effective imaging without compromising safety.

• Composition:

  • Store in a lead glass shield; the product should be utilized within 4 hours post-reconstitution to ensure effectiveness and reliability of imaging results.

• Areas of Normal Uptake:

  • Distributes through organs expressing SSTR such as pituitary, thyroid, kidneys, pancreas, prostate, liver, and salivary glands, providing essential guidance for diagnoses and treatment strategies.

Variants of Ga-68 Products

• Ga-68 Dotatoc (OCTEVY, FDA approval pending):

  • Exhibits binding to SSTR2 and SSTR5, improving specificity in imaging and potentially enhancing diagnostic accuracy.

• Ga-68 Dotanoc:

  • Binds to SSTR2, SSTR3, and SSTR5, expanding the scope of possible diagnostics for NETs and associated conditions.

• Ga-68 Dotatate (NETSPOT):

  • Binds specifically to SSTR2 with a higher affinity (10x), enhancing effectiveness in monitoring treatment response and tumor progression.

Comparison of Ga-68 vs. Cu-64:

• Cu-64 offers improved spatial resolution with a lower effective positron range, crucial for detecting small lesions, thereby enhancing diagnostic capability.

• However, it requires higher doses for equivalent scan counts, impacting patient safety considerations, necessitating ongoing evaluation.

Comparison of Half-lives and Positron Energies

Implications of Positron Energies

• Lower-energy, shorter-range positron emitters improve PET spatial resolution, vital for accurate tumor delineation, significantly impacting patient outcomes.

• The shorter range positively influences image quality, reducing scatter and enhancing diagnostic reliability, essential in complex cases involving neuroendocrine tumors.

Normal Biodistribution of Radiopharmaceuticals

• 68Ga-DOTATATE vs. 64Cu-DOTATATE:

  • Show similar biodistribution patterns; however, less splenic uptake is observed in 64Cu-DOTATATE, allowing clearer imaging in patients with organ complexities and creating opportunities for more accurate diagnosis and treatment planning.

NET Imaging Protocols

Indications

• Indicated for initial diagnosis, engagement in peptide receptor radionuclide therapy (PRRT), and post-therapeutic assessments, fostering a multifaceted approach to NET management.

• Note the challenge posed by low somatostatin receptor expression in some NETs; integration of 18F-FDG PET may supplement in such cases to guarantee comprehensive assessment and improve accuracy in treatment determinations.

Patient Preparation:

1. Discontinue short-acting somatostatin analog (SSA) medications 12 hours prior.

2. Discontinue long-acting SSA medications 3-4 weeks prior to imaging protocols.

3. Encourage hydration pre- and post-injection to improve imaging outcomes and reduce discomfort for patients.

Dosage Recommendations

• Ga-68 Dotatoc (OCTEVY):

  • Recommended dose similarly aligns to 4 mCi, falling within the 3-5 mCi range, based on ongoing FDA application reviews.

• Pediatric dosage: 1.59 MBq/kg (0.043 mCi/kg), ranging from 11.1 MBq to 111 MBq (3 mCi), ensuring safety considerations for the younger patient population.

• Guideline variations exist for Ga-68 Dotanoc and Dotatate, with Cu-64 maintaining a standard of 4 mCi for optimal imaging results.

Imaging Protocol Overview

• Uptake time varies for each radiopharmaceutical post-injection:

  • 68Ga-DOTATOC: 55-90 minutes.

  • 68Ga-DOTATATE: 40-90 minutes.

  • 64Cu-DOTATATE: 45-90 minutes.

• Utilize a scout/CT/PET scanning approach, ensuring correct positioning and adequate imaging time per bed position to capture high-quality images necessary for accurate diagnosis.

Somatostatin Receptor Imaging Protocol

1. Prepare by ensuring no long-acting SSA is present within the specified timeframe for medication prior to examination.

2. Administer appropriate doses based on patient weight, maintaining hydration protocols to mitigate potential discomfort inherent in the imaging process.

3. Scanning procedure in a 3D mode from skull vertex to mid-thighs retains overall diagnostic clarity, enhancing the ability to detect small or atypically located lesions.

Normal Biodistribution Insights

• Typical intense locations include kidneys, bladder, spleen, and liver; these markers are crucial in diagnostics for detecting the presence and progression of neuroendocrine tumors.

• Variability in uptake time post-injection suggests careful timing during imaging to ascertain diagnostic accuracy, mitigating complications in treatment decisions among varied patient presentations.

General Interpretation Guidelines

• Images are to be interpreted by trained professionals, focusing on areas of uptake against standard physiological biodistributions, enhancing accuracy in diagnosis.

• Assess Krenning score for scintigraphy to determine radiotracer uptake relative to normal organ backgrounds, a crucial element in developing a treatment strategy tailored to patient needs.

  • Scores also assist in evaluating candidacy for PRRT, ensuring that appropriate therapies align with the patient's individual circumstances.

Krenning Score of NET Uptake

• Methodology:

  • Score 0: none

  • Score 1: significantly lower than liver

  • Score 2: equivalent to or slightly less than liver

  • Score 3: greater than liver

  • Score 4: greater than spleen

Application of Krenning Score

• Used to evaluate eligibility for PRRT, requiring scores typically above 2 for favorable treatment outcomes, enhancing patient prognostic evaluations.

• False-positive rates prompt the necessity for correlation with clinical context factors such as serum markers to ensure accurate diagnosis, advocating for individualized approaches in management strategies.

SSTR-RADS Score

• 1-2: Likely benign

• 3A-3D: Equivocal

• 4-5: Positive indicating candidacy for PRRT therapy, profoundly affecting the treatment protocol and decision-making process.

Additional Considerations in Imaging

• Set preparatory measures if initiating Ga-68 or Cu-64 imaging for the first time, ensuring consistency in diagnostic accuracy across subsequent imaging procedures.

  • Equipment adjustments and calibrations are necessary for precise SUV calculations based on the isotope used, directly impacting treatment planning and patient management effectiveness.

Normal Variant Observations

• Thymus Functionality: Elevated SSTR expressions can cause detectable uptake in thymic lymphoid tissues on imaging, complicating interpretations and necessitating experienced radiological evaluations.

• Splenule Characteristics: Intense uptake should demonstrate stability compared to prior imaging, fostering diagnostic reliability and proper documentation of changes over time.

Clinical Case Examples

• Focal uptake in a pancreatic NET: Demonstrates localized tumor activity without evidence of metastasis, emphasizing the importance of regular monitoring strategies.

• Visualization in metastatic NETs: Highlights the need for comprehensive imaging protocols in small bowel primary tumors that may be missed by conventional methods, reinforcing innovation in diagnostic approaches.

• Eligibility assessments for PRRT: Based on comprehensive imaging of multiple lesions, verifying sufficient SSTR expression and accounting for clinical progression, ensuring that tailored treatments effectively meet patient needs.

Conclusion and Questions

• Open forum for inquiries regarding lecture content, concepts, and discussion points from specific case studies to foster an interactive learning environment for all attendees, promoting thorough understanding and application of knowledge in clinical practice.